Company: THC
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000070318-25-000009
Chunk: 160

Company: TENET HEALTHCARE CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 160
---
OL carryforwards or tax credit carryforwards at the time of ownership change.

NOTE 20. EARNINGS PER COMMON SHARE

The following table reconciles the numerators and denominators of our basic and diluted earnings per common share calculations. Net income available to our common shareholders is expressed in millions and weighted average shares are expressed in thousands. Net Income Available to Common Shareholders (Numerator)Wtd. Avg. Shares(Denominator)Per-ShareAmountYear Ended December 31, 2024   Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$3,200 96,904 $33.02 Effect of dilutive instruments1 977 (0.32)Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$3,201 97,881 $32.70 Year Ended December 31, 2023   Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$611 101,639 $6.01 Effect of dilutive instruments(13)3,161 (0.30)Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$598 104,800 $5.71 Year Ended December 31, 2022   Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share$410 106,929 $3.84 Effect of dilutive instruments8 3,587 (0.05)Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share$418 110,516 $3.79 Dilutive instruments during the years ended December 31, 2024, 2023 and 2022 consisted of stock options, RSUs, deferred compensation units and dividends on subsidiary preferred stock. For portions of these years, our dilutive instruments also included certain convertible instruments, including: RSUs issued under the USPI Management Equity Plan until they were repurchased in October 2024, an agreement related to the ownership interest in a Hospital Operations segment joint venture during 2023 and 2022, and the Baylor Put/Call Agreement during the first six months of 2022.

NOTE 21. FAIR VALUE MEASUREMENTS

We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values